FLGT
Fulgent Genetics Inc
21.50$
-0.7%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 33.5% | 50.2% | 87.6% | 79.7% | 78.8% | 41.8% | 74.8% | 47.9% | 45.3% | 41.1% | 29.0% | 45.4% | |
| 8.1% | 8.4% | 13.6% | 11.4% | 12.2% | 13.5% | 12.5% | 12.9% | 5.7% | 7.9% | 4.5% | 4.1% | |
| 8.1% | 8.4% | 80.1% | 72.6% | 68.0% | 31.9% | 42.7% | 35.2% | 38.0% | 34.3% | 21.2% | 27.7% | |
| 18.3% | 37.0% | 7.5% | 7.1% | 11.3% | 8.1% | 29.1% | 11.2% | 5.4% | 4.7% | 6.3% | 7.5% | |
| 6.7% | 3.6% | 0.6% | 0.4% | 0.6% | 0.3% | 2.4% | 1.0% | 0.3% | 0.5% | 0.7% | 0.9% | |
| 46.1% | 42.3% | 10.7% | 12.8% | 11.7% | 9.7% | 5.7% | 4.9% | 7.1% | – | – | – | |
| – | – | 0.0% | 0.0% | – | – | 0.0% | 4.0% | 10.3% | 1.8% | 1.8% | 2.1% | |
| – | – | 0.0% | 0.0% | – | – | – | 2.8% | 10.9% | 11.6% | 11.1% | 11.0% | |
| 20.6% | 11.8% | 6.1% | 5.1% | 5.0% | 6.7% | 18.7% | 8.8% | 8.4% | 8.3% | 7.4% | 8.8% | |
| 20.6% | 11.8% | 6.1% | 5.1% | 5.0% | 4.2% | 18.6% | 8.2% | 6.4% | 5.9% | 6.0% | 7.0% | |
| – | – | – | – | – | 0.5% | 2.2% | 1.7% | 1.9% | 0.4% | 0.2% | 0.2% | |
| 7.8% | 5.4% | 4.7% | 3.7% | 2.4% | 1.8% | 3.8% | 1.6% | 1.7% | 1.2% | 1.5% | 1.5% | |
| – | – | 0.0% | 0.0% | – | – | – | – | 0.2% | 0.2% | 0.2% | 0.2% | |
| 79.4% | 88.2% | 93.9% | 94.9% | 95.0% | 93.3% | 81.3% | 90.6% | 91.4% | 92.0% | 92.9% | 91.6% | |
| -486.6% | -911.5% | -95.0% | -101.3% | -114.5% | -71.5% | 21.5% | 51.4% | 57.8% | 51.3% | 48.4% | 43.7% | |
| 833.8% | 218.9% | 30.5% | 31.1% | 32.7% | 21.1% | 3.4% | 2.4% | 2.2% | 2.4% | 2.5% | 2.5% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.